Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743860 · ClinicalTrials.gov registry record · Phase 1
A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00743860 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 20 participants.
The verdict
NCT00743860, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is designed to assess the pharmacokinetics of darapladib and its metabolites following single and 28 days of repeat dosing of darapladib.
Interventions
- DRUG darapladib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743860
The ClinicalTrials.gov registry entry for NCT00743860 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which darapladib is the first listed.
NCT00743860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00743860 about?
NCT00743860 is a clinical study titled "A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848". This study is designed to assess the pharmacokinetics of darapladib and its metabolites following single and 28 days of repeat dosing of darapladib.
What is the current status of trial NCT00743860?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2008-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00743860?
The interventions under investigation include: darapladib (DRUG).
Who is sponsoring clinical trial NCT00743860?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.